Latest news with #Associates
Yahoo
4 days ago
- Business
- Yahoo
Consumers- What Confidence and Costco Tell Us About the Spending Outlook
The good news recently was that the Conference Board announced its consumer confidence index surged in May to 98, up from 85.7 in April. Especially encouraging is that the expectations component soared to 72.8 in May, up from 55.4 in April, notes Louis Navellier, founder and chairman of Navellier & Associates. To get a FREE copy of the complete MoneyShow 2025 Top Picks Report, click HERE.) Other components, like business conditions, employment prospects, and future income also rose in May. So, after consumer confidence declined for five straight months, the May resurgence is very hopeful for the summer, since consumers are now suddenly upbeat! ( Louis will be speaking at the 2025 MoneyShow Masters Symposium Las Vegas, scheduled for July 15-17. Click HERE to register.) Another good sign of consumer confidence is that Costco Wholesale Corp. (COST) announced its earnings on Thursday, with quarterly same-store sales rising 8%, which is a sign that consumer spending remains strong. Since Costco is a major gasoline retailer, the fact that its same-store sales rose despite lower gasoline prices is an important signal. Costco will also be key to helping move the bloated inventory of goods that were 'dumped' in the US in the first quarter in an effort to beat the coming US tariffs. The company has stockpiled many goods, such as patio furniture, with no price increases foreseen for the summer months. See also: CTRI: A Utility Play That Just Landed Large, New Contracts All in all, the Commerce Department reported that personal spending rose only 0.1% in April after surging 0.7% in March. The data is not very inflationary, so the Federal Reserve has all the reasons its needs to cut key interest rates as soon as it can overcome its inflation fears. Disclosure: Navellier & Associates owns COST in managed accounts. Louis Navellier and his family own COST via a Navellier managed account and in a personal account. More From SPX: Yes, We Could Finish 2025 at 6,600 Given Earnings, AI Growth Earnings, Jobs Data to Drive Next Market Moves Market Minute 6/3/25: Wet-Blanket Forecasts Weigh on Markets Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Q1 2025 ARS Pharmaceuticals Inc Earnings Call
Justin Chakma; Chief Business Officer; ARS Pharmaceuticals Inc Richard Lowenthal; President, Chief Executive Officer, Director; ARS Pharmaceuticals Inc Eric Karas; Chief Commercial Officer; ARS Pharmaceuticals Inc Kathleen Scott; Chief Financial Officer; ARS Pharmaceuticals Inc Ryan Deschner; Analyst; Raymond James & Associates, Inc. Josh Schimmer; Analyst; Cantor Fitzgerald Roanna Ruiz; Analyst; Leerink Partners Lachlan Hanbury-Brown; Analyst; William Blair & Company, L.L.C. (Research) Andre Argyrides; Analyst; Oppenheimer & Co., Inc. Louise Chen; Analyst; Scotiabank GBM Operator Good morning, and welcome to the ARS Pharmaceuticals conference call. (Operator Instructions) Please be advised that today's conference is being recorded.I'll now turn the call over to Justin Chakma, Chief Business Officer. Please proceed. Justin Chakma Good morning, and thank you for joining our first-quarter 2025 earnings conference call. This morning, we issued a press release detailing our financial results and commercial highlights, which is available in the Investor and Media section of our website at me on the call are Richard Lowenthal, our Co-Founder, President, and CEO, who will review recent corporate updates and achievements; Eric Karas, our Chief Commercial Officer, who will cover our commercial activities and progress; and Kathy Scott, our CFO, who will provide a summary of our financial results and cash we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. Please refer to our press release and SEC filings for further risk that, I'll turn the call over to Rich. Richard Lowenthal Thank you, Justin. Good morning, and thank you all for joining us on this off to a strong start in 2025 as we continue to execute the nationwide launch of neffy, the first and only needle-free epinephrine treatment approved for Type I allergic reactions, including anaphylaxis. We believe neffy has blockbuster potential, addressing a US market potential of $3 billion net sales in the near term, comprised of about 6.5 million patients who have been prescribed epinephrine over the past three this, an additional 13.5 million diagnosed patients have no epinephrine prescription, and many struggle with needle anxiety and portability concerns. Only 3.2 million patients actually fill their epinephrine autoinjector prescriptions, underscoring the substantial unmet medical need that neffy is uniquely positioned to only two quarters of commercialization so far, neffy is gaining traction as a potential new standard of care in this space. In the first quarter of 2025, neffy generated $7.8 million in US net product revenue, reflecting the continuously growing demand among physicians, patients, and caregivers for an alternative to traditional autoinjectors. We started this year with 27% commercial insurance coverage and now have reached 57% coverage, with more payer discussions are entering the peak epinephrine prescribing season during this summer with strong momentum. And with additional health insurance coverage anticipated in the coming months, we also expect to generate additional demand through our DTC consumer awareness campaign that launches tomorrow. This demand is supported by the real-world evidence of adoption by thousands of healthcare providers who have prescribed neffy already. In addition, thousands more have participated in our neffy Experience Program, using neffy during oral food challenges and immunotherapy treatments in the month, we also reached a major milestone. In addition to our 2-milligram dose for children and adults weighing 30 kilograms or greater, neffy 1-milligram was approved by the FDA in early March of this year and is now available at pharmacies across the US for children weighing between 15 and 30 kilograms. The availability of this pediatric dose is particularly important, as the 1-milligram dose represents 23% of all epinephrine units dispensed in 2024, and more than half of all epinephrine prescriptions for children. neffy offers caregivers and young patients a reliable and easy-to-use option, and we ensured that it was available before summer travel, camps, and back-to-school further strengthen our commercial reach, including to key pediatricians, we recently expanded our strategic collaboration with ALK-Abelló, a global leader in allergy care, ahead of this peak summer prescribing season. This co-promotion agreement expands our direct promotional network for neffy to over 20,000 healthcare providers across the United States, including targeted outreach to approximately 9,000 pediatricians, accelerating our efforts to position neffy as the leading epinephrine option for both adults and partnership builds on our broader global relationship with ALK. Under this agreement, ARS will continue to focus on allergists and the highest volume pediatricians and PCPs in the United States and retains full control over all aspects of US commercialization, including marketing, medical affairs, market access, production, and distribution. Lastly, regulatory reviews are underway for neffy in the UK, Canada, Japan, China, and Australia, with decisions and commercial launches in these countries expected to begin in mid-2025 through the first half of summarize, this is a year of execution for ARS. We aim to deepen physician engagement, expand access, and lay the groundwork for a global commercial footprint for neffy, supported by our partners.I'll turn the call over to Eric for a more detailed review of our commercial progress. Eric Karas Thanks, commercial strategy is built on three key pillars: driving healthcare provider adoption, securing market access, and increasing patient awareness. Since launch, our sales team has directly engaged over 10,000 healthcare providers. More than 50% of these providers have prescribed neffy. Of the prescriptions submitted to date, nearly 90% have come from top-decile targets. We view this as a strong endorsement from leading experts who treat the highest number of patients at risk for allergic 2,500 healthcare providers have also enrolled in our neffy Experience Program, and over 13,000 units have been placed in offices for use during anaphylactic events. This hands-on experience has led to numerous physician testimonials that highlight the positive impact neffy is having in clinical practice. With the recent availability of the 1-milligram dose, we'll be adding it to our neffy Experience Program, and we'll collect additional information on both the 1-milligram and 2-milligram doses. We plan to share the physician survey data from our neffy Experience Program in various medical forums later this Rich mentioned, we continue to make progress in payer access. We have secured commercial coverage across more than 30 formulary platforms, now including UnitedHealthcare. Currently, over 57% of all US commercial life have access to neffy. We are approaching a tipping point in market access that will enable more healthcare providers to prescribe neffy without the coming months, as patients schedule appointments and visit their allergy care providers, we anticipate that access to neffy will become quicker and easier. For patients with commercial insurance, our assistance program ensures that most individuals will only have a $25 copay, which is less than the typical $40 for a generic are making it easier for patients, as the copay support is now automatically applied at the point of sale in retail pharmacies. Additionally, for eligible patients who are uninsured or underinsured, we provide neffy at no cost through our Patient Assistance Program. These programs reflect our commitment to ensure that all patients at risk of an allergic reaction have access to this potentially life-saving we turn to the third pillar of our commercial strategy, patient awareness, we are excited to announce the launch of a broad and comprehensive direct-to-consumer campaign that will redefine the epinephrine landscape and establish neffy as a household name. Our campaign, titled Hello neffy, Goodbye Needles, will debut tomorrow. We are utilizing a multi-channel strategy to reach patients, parents, and caregivers where they are, including connected TV, broadcast, social media platforms, health-related websites, prints, pharmacies, and point-of-care data-driven media plan aims to engage high-value audiences during key seasonal periods, such as back to school and the availability of our 1-milligram dose. We expect to reach 95% of severe allergy patients and their investment is essential for achieving our goals of raising awareness and encouraging adoption. Every aspect of this campaign is designed to empower patients and their caregivers to position neffy as a standard of care and drive prescription growth. We believe our DTC campaign could generate significant revenue in the second half of 2025 and beyond while establishing neffy as a leading brand in severe allergy care.I'll now pass the call over to Kathy to walk through our financials. Kathleen Scott Thank you, Eric. The details of our financial results can be found in our earnings press release and 10-Q filing, so I'll provide a the first quarter of 2025, we recorded total revenue of $8 million. This is comprised of $7.8 million in US net product revenue for neffy, and we expect to see a continued ramp-up in product revenue as our commercial efforts accelerate. In addition, we had $0.2 million in collaboration revenue, which was the recognition of deferred revenue from performance obligations related to our collaboration and license agreement with our new co-promotion agreement with ALK, ARS will continue to recognize all net product revenue in the US and retain full responsibility for commercialization. neffy will be detailed by ALK sales representatives in primary position for the first two years and co-primary position during the last two years of the four-year agreement. Additional terms of our co-promotional agreement can be found in our 8-K and 10-Q terms of our operating expenses, cost of goods sold for the first quarter was $1.1 million. Our COGS continues to benefit from some inventory that was expensed prior to FDA approval in August 2024.R&D expenses for the first quarter were $3 million, primarily related to clinical expenses and product development. Sales, general, and administrative expenses were $41.1 million for the first quarter, largely tied to personnel, sales, and marketing expenses associated with the commercialization of neffy in the Eric noted, we are launching a comprehensive DTC campaign tomorrow, which has a planned investment of $40 million to $50 million for the remainder of 2025. The bulk of this expense will be recognized in our SG&A in the second and third quarters of the year, and we believe we will start seeing the benefits of the DTC campaign starting in Q3 with the planned DTC spend and additional investments in pediatric access and commercialization with our partner ALK, we project total 2025 operating expenses of between $210 million and $220 million, excluding stock-based compensation and cost of goods sold. The ALK co-promotion agreement adds approximately $8 million in operating expense to the previous guidance for 2025. We believe this is a solid investment in our future growth potential in the pediatric portion of the commercial expenses under the co-promotion agreement with ALK will be recorded as an expense on our P&L for the first year of the agreement, but will accrue and not be paid in cash to ALK until the second year of the agreement. Any future performance-based payments to ALK based on achieving certain market share thresholds are expected to be recognized as operating we reported a net loss of $33.9 million, or $0.35 per share, for the first quarter. Overall, we are well capitalized today with a disciplined and strategic investment approach to support the commercial execution of neffy while also advancing development of our nasal epinephrine program in new indications such as of March 31, 2025, we had cash, cash equivalents, and short-term investments of $275.7 million. We reiterate today that based on our current plans, we have an operating runway of at least three that, I'll pass the call back over to Rich. Richard Lowenthal Thank you, you heard, we are executing from a position of strength. We've seen the momentum across the board, from strong early revenue and formulary wins to physician testimonials and real-world adoption. This reinforces our belief that neffy is a truly transformative product. I am proud of the work our team has done, and I'm grateful to our partners, the medical and advocacy communities, and above all else, the patients and caregivers for their support and please open the line for questions. Operator (Operator Instructions) Ryan Deschner, Raymond James. Ryan Deschner Good morning. Thanks for the question. I'm curious how much of the 1Q sales figure is attributed to inventory and how you're thinking about inventory [contribution] over the next two quarters, going into the peak epinephrine season as well as following it, and I have a follow-up. Richard Lowenthal Yeah, hi. This is Rich Lowenthal, Ryan. Our first-quarter numbers were very little influenced by inventory. We're seeing fairly steady inventories at this point, and it was prior to the 1-milligram being launched, so this was all 2-milligram sales, of course. But we don't think anybody had much influence on the sales this quarter. Ryan Deschner Got it. And what would the growth in that discount look like in the first quarter? How meaningful would that change from fourth quarter to first quarter? Richard Lowenthal Kathy can give you the full details, but as expected, the growth in that will slowly come down towards the 50% mark. We're seeing a good uptake of insurance coverage and fewer cash sales, and that will obviously bring down our gross to net when we get better insurance Kathy, do you want to speak to the gross to net in this quarter? Kathleen Scott Sure. Good morning, Ryan. Yes, Q4 was definitely a higher gross to net than Q1. As Rich said, our payment coverage is coming online, and we were kind of hovering around the 60% -- a little over 60% for Q1, but do expect that to go down to closer to 50% as we go forward in 2025. Ryan Deschner Thanks, Kathy. Thanks, Rich. Operator Josh Schimmer, Cantor. Josh Schimmer Thanks for taking the questions. Just a couple of quick ones. First, when you've worked through the inventory on hand, what do you expect cost of goods to settle out at? And then for the, I think, 50% of commercial lives that have access, can you confirm that there are no prior author requirements for access to neffy for them? Richard Lowenthal Sorry. Can you repeat the second question, Josh? Josh Schimmer The update was over 50% of commercial lives have access to neffy. Just want to make sure that there are no prior author requirements for those patients. Richard Lowenthal Right. Okay, so let's start there. Currently, about 57% of people have coverage with no prior authorization. If you count with prior authorization, we're probably close to 90%, Josh. So we're not really considering the prior authorization as a full coverage, partial but not do see good approval rates of prior authorizations between 60% and 80%, depending on the insurer. But again, we've got to get the doctors to write those prior authorizations. So that's a barrier. But 57% right now have coverage on neffy without any prior authorization or any other paperwork required. They can get a prescription, go to the pharmacy, and pick up the prescription at the then with regards to the first question, I don't believe we've given details on the COGS, other than generally the cost of goods are in the ballpark of less -- they're pretty low. I don't think we've given exact guidance. Have we, Justin, on this? Justin Chakma No. I think the question was whether, as we use up our inventory, what happens to cost of goods. Richard Lowenthal Kathy, do you want to speak to that? Kathleen Scott Sure. No, we definitely have, as included in our 10-Q, we've got some no-cost inventory that was expensed prior to FDA approval. So as we wean that into our inventory, which should be kind of over the next 18 months or so, we would expect that inventory at COGS would -- the COGS would increase slightly. But for the most part, that zero-cost inventory is the raw material. So we're still paying for manufacturing for those -- for the inventory that's being COGS in the near term. Josh Schimmer Okay. Thank you. Operator (Operator Instructions) Roanna Ruiz, Leerink Partners. Roanna Ruiz Hey. Morning, everyone. A couple for me. Could you talk about the strength of the neffy Experience Program in helping to convert possible later adopter physicians into broader prescribers of neffy? And what has the feedback been so far in terms of some details you've heard recently about use of neffy there? Any updates on single versus twice dosing of neffy, for example? Richard Lowenthal Yeah. So I can give you a little update. So as Eric pointed out earlier, where the neffy Experience Program's been very, very successful, more than 2,500 physicians are enrolled and have neffy. A lot of them have used everything we provided. So we are going to be expanding the program to not only include the 1-milligram, but possibly also for those doctors that have already used their supply of neffy 2-milligram to give them additional supply of the outcome so far, we're seeing very good results just by surveying the sites that have actually administered neffy to patients. The experiences are coming back very positive. We're still -- the results are basically looking like injections. So still around 90% are getting a response with a single dose of neffy; about 10% are needing a second dose. That's the same as what's observed with injection. So we believe that's very positive in general, the doctors have been very positive about their experience so far. So we are planning to potentially publish some of this shortly. We could then obviously be able to use that to help other doctors that may be still reluctant or still questioning whether real-world data is available, because this is a very large subset of real-world data right then we are looking forward to the 1-milligram being out there and being used as well, since a lot of these children that get oral food challenge are younger. And then maybe towards the American College meeting, we may also put out an abstract on the neffy Experience Program and the results. Roanna Ruiz Got it. That helps. And a quick follow-up from me. On the payer front and insurance coverage, how are you tracking against your goal of, I think, 80% commercial lives by 3Q? And could you remind us, are there any payers still in negotiations or in progress right now that you would need to secure to get there? Richard Lowenthal Yeah. I think, well, there's certainly a number of payers that we're still working with. We do have the contract with Zinc, but we're still working with Caremark and Aetna to cover neffy under that agreement. So that's obviously a big insurer that we're still working with to get final agreement also working with Prime and other Blue Cross companies, of course, to get an agreement with a lot of them. We do have some Blue Cross companies already covering. We generally have a scorecard on our website, so it's fairly transparent as to who's covering and who's still pending again, even Caremark right now is accepting PAs and approving at a very high percentage, as I said, in the upper range of the 60% to 80% I mentioned. So they are very, very quickly approving of prior authorizations, but they are still requiring a prior authorization for neffy at this point. But we are trying to work through those are some of the bigger ones that we want to try to get across the finish line to get towards that 80% coverage. But in general, with prior authorization, we're already above 90%. There's only a handful of companies that are actually blocking neffy right now, so that's actually very positive as well. Roanna Ruiz Yeah, sounds good. Thanks. Operator Lachlan Hanbury-Brown, William Blair. Lachlan Hanbury-Brown Hey, guys. Thanks for the questions. I was wondering if you could provide any detail on the number of prescriptions that were actually written and filled in the quarter as we try to understand what the sort of capture rate of IQVIA and other providers are. And could you provide any color on -- you've talked about the PAs and the high success rate there. Can you talk about how many of the prescriptions in the past quarter have been covered versus required prior off? Richard Lowenthal Okay. I think, Eric, you should probably take that question. Eric Karas Sure. Sounds good. So first, when we look at the prescription data through IQVIA, we've talked about this before, and it's not 100% capture of everything. Our cash prescriptions through Blink are not covered. But roughly, if you look at the extended unit data on a weekly basis, it's about 13,000 prescriptions or units. But again, that's not a complete then as far as the PAs, if you look at the beginning of this year, we were looking at about 70% of prescriptions required a PA. That's down to about 45%. So as Rich went through and I went through our comments, we're seeing the PAs come down, which is a very positive work closely with the doctors and obviously their staff to submit the PAs. We're continuing to drive that. And I think with six to seven months under our belt, we have really good insights in terms of the criteria that's evaluated in terms of an approval of the PA. So our sales team continues to share that information with office managers and those individuals in the office that are responsible for those PAs. Lachlan Hanbury-Brown Great, thanks. Could you also talk about the sort of overlap between the neffy experience docs and the high prescribers? I mean, are the 2,500 odd doctors in the neffy Experience Program, are they all in that sort of the high prescribing bucket at the moment? How's that sort of conversion looking? Eric Karas Yeah. Rich, I can take that one, too. So when we start looking at kind of our, first, I'll say from a decile perspective, about 81% of our decile 10s, that's the highest volume of physicians, are writing for neffy, which is great. If you look at the combination of 8s, 9s and 10s, it's about 75%. We do see that doctors that are part of the experience program, on average, are writing about 2.5 to 3 times more than the overall average that we're seeing at a national that program is exactly doing what we expected in terms of building trust and confidence. Doctors really like it because they're able to get firsthand experience. And when they talk to patients, they can reference that and tell stories about what they've seen in their own clinical as Rich said, we're looking to get that out more broadly in the second half of the year. But we're starting to do that already, too, with our peer to peer education, our speaker programs. Most of the speakers are part of the program and have had firsthand experience. So they're able to share that when they're speaking to other healthcare providers and their peers. So we're going to continue to drive that because we clearly know that this program is really hitting the mark of what we expected it to do. Lachlan Hanbury-Brown Got it. Thanks. Operator Andre Argyrides, Oppenheimer. Andre Argyrides All right. Good morning, and thanks for taking our question. Sorry for the disruption there earlier. Rich, can you just talk about how you're thinking about the rest of the year in terms of -- I know you're not providing guidance, but how the Q1 results are tracking for that inflection point in the second half of the year? Thanks. Richard Lowenthal Yeah. I think we're still tracking according to plan and exactly where we believe we should be right now. We are obviously expecting to see that inflection in the third quarter. The August-September timeframe tends to be peak sales for this product, especially with the sales are still heavily weighted towards children with the 2-milligram. We expect that to even be expanded, greater focus on children with the 1-milligram. So we do expect to see that inflection point start this summer. And with the DTC campaign and 1-milligram available, we think that that's where we'll start to see a real upturn in market share. Andre Argyrides And then just a quick follow-up, do you still think that prior offs are the biggest impediment at the moment? And so when you get to the broader access that you're guiding towards that that will be a real a real boost. Richard Lowenthal Yeah. I mean, I think the prior authorizations when we have low insurance coverage is an impediment when we start to get higher and higher up in insurance coverage. There is fewer prior off the docks have to deal with. And they're more than happy to write prior authorizations. They just don't want to write too many. So it's a matter of so we do see the number of prior authorizations coming down. We see the approval rates increasing. So that's a good sign. And that encourages doctors to continue to write prior authorizations for those patients that are not getting automatic insurance coverage without paperwork. So that's we do think it's a headwind. But it becomes less and less and less as time goes by, because the remaining patients that are not covered are those insurance companies that are delaying. They're -- the doctors are more willing to write the prior authorizations because there's just fewer of that make sense? Andre Argyrides It does. Thanks, and congrats on the quarter. Thanks. I'll jump back to the queue. Operator Louise Chen, Scotiabank. Louise Chen Hi. Thanks for taking my questions here. So I just wanted to ask you how we can think about the sales targets that ALK has to hit in order to get to the performance-based payments that you've then the second thing is, what is your market share now? Where do you hope to be by the end of the year? Thank you. Richard Lowenthal Eric, I think you should take that question, if okay. Eric Karas Yeah, let me take the second part first. So when you look at a market share overall in the category of the basket of epinephrine across the board, brand and generic, we have about a 1.3% share. But what we also focus on, more importantly, is our targets of the doctors that we're calling on directly. That's about 6.2. And then we also have super targets, which is about 7.5. So these are doctors that we spend extra time in in terms of our promotion and far as the ALK co-promote, this is a great opportunity that we are very excited about. Obviously, we're able to expand our footprint, the number of reps. We're going to grow from about 12,500 positions with direct promotion up to about 20,000. So we have some milestone targets in terms of market share that we think is very reasonable to hit those especially, as we've articulated, we've got so many catalysts coming up in the next three to six months here with the 1-milligram, the DTC commercial, and continued pair coverage improving. So we feel really confident about this co-promote and look forward to the impact that they're going to have in the pediatric space. Louise Chen Okay. Thank you. Operator Lachlan Hanbury-Brown, William Blair. Lachlan Hanbury-Brown Hey, thanks for the follow-up. I just wanted to confirm, Kathy, I think you said you're expecting most of the DTC marketing to be in Q2 and Q3. So I wanted to confirm, should we sort of expect a tail off in Q4, or is it more that most of the sort of growth will be Q2 and Q3 and then it will be steady thereafter? Kathleen Scott Sure, we do expect to spend some in Q4, but as I said in my remarks, the majority in Q2 and Q3. And as Rich said, the inflection point for sales, we would expect to start really in does that answer your question? Lachlan Hanbury-Brown Yeah. Thanks. Richard Lowenthal And Lachlan, just to add to that, I mean, we obviously are doing that very intentionally to front-load the awareness campaign before the summer period, which is really August, September is where you'll see the big peak in epinephrine sales. So we want to make sure we get to all the consumers and make sure they're aware the neffy is available. So the sooner we can do that in the summer period, the better. So we've obviously put a lot of the spend earlier and then we'll taper off after that and get to a steady state. Lachlan Hanbury-Brown Okay. Thanks. Operator Thank you. And with that, ladies and gentlemen, we conclude our Q&A session and program for today. Thank you all for participating. You may now disconnect. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Alarm.com (ALRM) Q1 Earnings Report Preview: What To Look For
Home security and automation software provider (NASDAQ:ALRM) will be announcing earnings results tomorrow afternoon. Here's what to expect. beat analysts' revenue expectations by 1.4% last quarter, reporting revenues of $242.2 million, up 7.1% year on year. It was a mixed quarter for the company, with a decent beat of analysts' billings estimates but full-year guidance of slowing revenue growth. Is a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting revenue to grow 4.9% year on year to $234.3 million, slowing from the 6.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.47 per share. Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.9% on average. Looking at peers in the software-as-a-service segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Manhattan Associates delivered year-on-year revenue growth of 3.2%, beating analysts' expectations by 2.3%, and Pegasystems reported revenues up 44.1%, topping estimates by 33.1%. Manhattan Associates traded up 5.8% following the results while Pegasystems was also up 28.8%. Read our full analysis of Manhattan Associates's results here and Pegasystems's results here. There has been positive sentiment among investors in the software-as-a-service segment, with share prices up 17% on average over the last month. is up 6.3% during the same time and is heading into earnings with an average analyst price target of $69.88 (compared to the current share price of $52.68). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
CNBC
01-05-2025
- Business
- CNBC
Billionaire Lukas Walton names new CIO for his family office
Builders Vision, the family office of billionaire Walmart heir Lukas Walton, has promoted Noelle Laing to chief investment officer. The Chicago-based firm uses philanthropy and impact investing to address three global challenges: clean energy, food sustainability and ocean health. Laing started working with Walton 12 years ago when he was a client at Cambridge Associates, where she managed impact investments. She joined Builders Vision in 2019 and has served as CIO of the firm's philanthropy arm, Builders Initiative, since 2022. In that capacity, Laing shifted 90% of the $1.7 billion endowment to "mission-aligned investments" that advance social and environmental causes and led a team that invested more than $300 million in early-stage startups and fund managers. In her new role across the full family office, Laing will also oversee some family trusts and the firm's asset management arm. A spokesperson told CNBC that Builders Asset Management has a multibillion-dollar taxable portfolio but declined to specify its size. "Noelle has been instrumental in the success of our investment strategies and is the perfect person for the job," said Walton in an announcement. "Through increased coordination and shared vision, we can be even more effective at pursuing these goals across our sectors." Laing is consolidating the two divisions' investment teams and will oversee about 20 investors. She plans to make about a half dozen hires, bringing the team's headcount to nearly 30. Builders Vision represents a growing class of family offices with assets and headcounts that rival those of institutional investors. Laing told CNBC that this scale allows Builders Vision to tackle its core causes in a wide range of ways spanning nonprofit grants, small bets on startups that are piloting new technology and multimillion-dollar co-investments and allocations to fund managers. "It's a spectrum of investments, and it allows us to really get a deep view of the different ways that we can get exposure and move oceans, food and agriculture and energy into the future," she said. "We can choose which tool in which portfolio to see that vision through." Builders Vision recently backed Norway's Bluefront Equity, a sustainable seafood fund. In November, the firm co-guaranteed $70 million of debt held by the Bahamas, allowing the government to borrow at a lower cost and allocate the savings to marine conservation. The Inside Wealth newsletter by Robert Frank is your weekly guide to high-net-worth investors and the industries that serve them. Subscribe here to get access today. Laing started her career at Cambridge Associates in 2003, leaving in 2008 to work at the Red Cross and a pension fund. She returned to the investment advisory in 2010. At Cambridge, she consulted on Walton's then-fledgling venture capital fund, S2G Investments. The $2.5 billion fund was spun off from Builders Vision in May 2024. Laing is part of a small but growing group of women managing investments for the ultra-rich including Erin Harkless Moore of Melinda French Gates' Pivotal Ventures and Margo Doyle of S-Cubed Capital, the family office of billionaire venture capitalist Mark Stevens. Rebecca Carland, now CIO of the Knight Foundation, served as CIO of Builders Asset Management until late last year. All four women are also alumna of Cambridge Associates, the top advisor to wealthy families, endowments and foundations with some 300 senior investment staff. David Jallits, another Cambridge Associates veteran, oversees investments for Chicago's Duchossois family. "You have so many resources and so many people's different opinions, which is such a big part of the magic of Cambridge," Laing said. "It's a great training ground for a place like Builders Vision where you can focus and then implement kind of the best ideas from from Cambridge."
Associated Press
09-04-2025
- Business
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Manhattan Associates
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Manhattan Associates To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Manhattan Associates between October 22, 2024 and January 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Manhattan Associates, Inc. ('Manhattan Associates' or the 'Company') (NASDAQ: MANH) and reminds investors of the April 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or defendants provided investors with material information concerning Manhattan Associates' expected revenue for the fiscal year 2025. Defendants' statements included, among other things, confidence in the Company's ability to forecast guidance despite macroeconomic fluctuations, the growth potential of their professional services offerings, and the ability for their cloud revenue to drive revenue for its professional services. On January 28, 2025, Manhattan Associates published its financial results for the fourth quarter and full fiscal year 2024 and announced reduced revenue guidance for the full fiscal year 2025. The Company attributed its results and lowered guidance on the 'shift in professional services work to future periods . . . and to a lesser extent, reduced customization and higher partner utilization.' Following this news, the price of Manhattan Associates' common stock declined dramatically from a closing market price of $295.10 per share on January 28, 2025, to $222.84 per share on January 29, 2025, a decline of about 24.49% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Manhattan Associates' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Manhattan Associates class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
